Results 31 to 40 of about 29,223 (218)
Redox Biology, 2020 Atrial fibrillation (AF) occurs in up to 11% of cancer patients treated with ibrutinib. The pathophysiology of ibrutinib promoted AF is complicated, as there are multiple interactions involved; the detailed molecular mechanisms underlying this are still ...
Xinyu Yang +12 more
doaj +1 more source
Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. [PDF]
, 2014 Ofatumumab is a humanized anti-CD20 monoclonal antibody that has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia. We conducted a phase II single-arm study at a single center.
Almahasnah, E +6 more
core +3 more sources
Regulation of B cell fate by chronic activity of the IgE B cell receptor. [PDF]
, 2016 IgE can trigger potent allergic responses, yet the mechanisms regulating IgE production are poorly understood. Here we reveal that IgE+ B cells are constrained by chronic activity of the IgE B cell receptor (BCR).
Allen, Christopher DC +6 more
core +1 more source
Synthesis, Functionalization, and Reactivity of Vinyl Sulfondiimidamides
Angewandte Chemie, EarlyView.Combining unsymmetrical sulfurdiimide reagents (R‐NSN‐R1) and Grignard reagents, followed by oxidative amination, delivers a series of vinyl sulfondiimidamides. Reactivity with cysteine and lysine derivatives is shown, and the cysteine reactivity is mapped in detail. Variation of the two imidic N‐substituents can be used to tune reactivity of these new
Katherine G. Rodden +4 more
wiley +2 more sources
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. [PDF]
, 2019 Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines. Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We discovered that treatment
Hasan, Md Kamrul +4 more
core +1 more source
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [PDF]
New England Journal of Medicine, 2015 Jan A Burger +2 more
exaly +2 more sources
Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
Frontiers in Immunology, 2023 IntroductionCytotoxic CD8+ T cell (CTL) exhaustion is a dysfunctional state of T cells triggered by persistent antigen stimulation, with the characteristics of increased inhibitory receptors, impaired cytokine production and a distinct transcriptional ...
Ling Li +12 more
doaj +1 more source
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves [PDF]
, 2016 To the Editor: Makkar et al. (Nov. 19 issue)(1) report possible subclinical leaflet thrombosis in up to 40% of patients involved in a clinical trial of transcatheter aortic-valve replacement (TAVR).
Burriesci, Gaetano +2 more
core +2 more sources
Blood Advances, 2018 : Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes +6 more
doaj +1 more source
eJHaem, 2021 Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017, represented a
Peter Hillmen +6 more
doaj +1 more source